Sakar Healthcare Ltd
SAKARSakar Healthcare Ltd
SAKAR
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 50.79 | 2.40 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sakar Healthcare ltd. is engaged in providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Liquid Injectables in ampoules and vials, and Dry Powder Injections.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 85.00 | 95.92 | 130.40 | 138.03 | 156.53 | 166.05 | ||||||
Raw Materials | 42.90 | 52.20 | 73.69 | 74.00 | 85.05 | 122.04 | ||||||
| Power & Fuel Cost | 3.31 | 2.26 | 3.01 | 2.90 | 4.25 | |||||||
| Employee Cost | 11.61 | 12.74 | 14.26 | 15.81 | 18.82 | |||||||
| Selling & Administrative Expenses | 4.49 | 4.36 | 5.60 | 6.85 | 6.92 | |||||||
| Operating & Other expenses | 1.12 | 0.58 | 2.26 | 0.66 | -0.06 | |||||||
EBITDA | 21.57 | 23.78 | 31.58 | 37.81 | 41.55 | 44.01 | ||||||
| Depreciation/Amortization | 7.08 | 8.06 | 9.67 | 14.99 | 18.05 | 19.49 | ||||||
| PBIT | 14.49 | 15.72 | 21.91 | 22.82 | 23.50 | 24.52 | ||||||
| Interest & Other Items | 2.26 | 2.48 | 2.90 | 5.95 | 7.59 | 6.91 | ||||||
| PBT | 12.23 | 13.24 | 19.01 | 16.87 | 15.91 | 17.61 | ||||||
| Taxes & Other Items | 2.60 | 2.55 | 3.76 | 4.12 | 4.23 | 5.20 | ||||||
| Net Income | 9.63 | 10.69 | 15.25 | 12.75 | 11.68 | 12.41 | ||||||
| EPS | 6.44 | 6.99 | 9.32 | 7.05 | 5.73 | 5.71 | ||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sakar Healthcare Ltd | 53.97 | 2.40 | — |
| Sun Pharmaceutical Industries Ltd | 46.13 | 6.58 | 0.73% |
| Cipla Ltd | 29.21 | 4.49 | 0.87% |
| Mankind Pharma Ltd | 62.91 | 12.57 | — |
Price Comparison
Compare SAKAR with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SAKAR has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Sakar Healthcare rose 31.87% to Rs 4.80 crore in the quarter ended September 2024 as against Rs 3.64 crore during the previous quarter ended September 2023. Sales rose 25.53% to Rs 42.78 crore in the quarter ended September 2024 as against Rs 34.08 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales42.7834.08 26 OPM %26.8827.46 - PBDT10.238.37 22 PBT5.114.15 23 NP4.803.64 32 Powered by Capital Market - Live
Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 22 October 2024.Powered by Capital Market - Live
Net profit of Sakar Healthcare declined 15.14% to Rs 2.41 crore in the quarter ended June 2024 as against Rs 2.84 crore during the previous quarter ended June 2023. Sales rose 5.54% to Rs 41.15 crore in the quarter ended June 2024 as against Rs 38.99 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales41.1538.99 6 OPM %26.0023.16 - PBDT9.768.47 15 PBT4.703.95 19 NP2.412.84 -15 Powered by Capital Market - Live
Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Sakar Healthcare announced that the 20th Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
Sakar Healthcare consolidated net profit declines 21.14% in the September 2022 quarter
Sakar Healthcare standalone net profit declines 93.89% in the December 2021 quarter
Sakar Healthcare standalone net profit declines 46.05% in the September 2021 quarter
Sakar Healthcare’s fully-integrated anti-cancer formulation unit now starts with Research Lab; Stock ends 2% up
Sakar Healthcare standalone net profit rises 40.93% in the June 2021 quarter
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant